The agreement would have Wyeth manufacturing Herceptin, used to treat women suffering from a form of metastatic breast cancer. Financial terms of the deal were not revealed.
Published in Brief:
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||